首页 > 社会贡献 > 全球社会贡献介绍

全球社会贡献介绍

全球社会贡献介绍

Our Social Contribution Goals

In line with Daiichi Sankyo's vision for 2015, which calls for us to become a Global Pharma Innovator, our most-important target is to be a company that we can take pride in because it is engaged in truly global business operations and also maintains a global perspective on social contribution activities. Of course, the Daiichi Sankyo Group is well positioned to contribute to society through its mainstay pharmaceutical business operations. Business operations, such as the development of a new anti-malaria drug which Ranbaxy is developing as well as the original drug discovery operations of Daiichi Sankyo, are directly linked to highly significant social contributions. On the other hand, contemporary global society is demanding that companies make additional contributions to supplement those directly stemming from their business operations, and we must do our utmost to respond to global society's expectations in this regard. The Daiichi Sankyo Group is a global enterprise with approximately 30,000 employees working in various locations around the world. Based on recognition that we are a powerful global enterprise capable of making important contributions, we would like to implement social contribution activities that are commensurate with our capabilities.

The Intention Behind Our Mobile Healthcare Service

One point is that, to ensure that our social contribution activities are in line with the Group's overall development strategy, we intend to develop activities undertaken by Daiichi Sankyo. Up to now, individual Group units have undertaken their own social contribution programs targeting issues that are particularly important for their individual countries or regions. Going forward, we believe it is important to coordinate the direction of the Group's social contribution programs and thereby augment the Group's overall corporate value more effectively. Another point is that, as a pharmaceutical company with global business operations, we want to make highly original initiatives of types that are not being made by competing companies. In this regard, it is worth noting that our mobile clinic services are leveraging the special capabilities of Daiichi Sankyo Group member Ranbaxy, which has accumulated know-how and resources in the course of its implementation of mobile healthcare services through RCHS. Because of this situation, we are not just simply intending to make a contribution to society we are seeking to make a distinctive contribution to society that reflects the special characteristics of Daiichi Sankyo. In addition, to ensure that our social contribution programs earn a high evaluation from society, it is important that we be able to generate clear-cut numerical results. Accordingly, we will be methodically monitoring how much improvement we make with regard to reducing the infant mortality rates and maternal mortality rates, and these results will serve as constructive feedback for planning subsequent programs. By sustaining the implementation of programs along with the design to improve existing programs based on feedback information, we intend to progressively enhance the quality and efficacy of our programs.

Global Programs for Regional Needs

Given that individual countries and regions have different values, cultures, social backgrounds, and economic conditions, it is difficult to unify the direction of global programs. There are different needs and expectations in each country and region. How should we overcome these challenges? We believe that there is a need to engage in thorough two-way communications activities with local societies to deepen the level of our mutual understanding with respect to each challenge.

了解更多

strategy
公司介绍

第一三共在中国已开展了三十年的业务,我们提供的医药产品覆盖各治疗领域.

更多...